Mountains, Rivers, and Dreams — Measured in Steps | Dalton Venture 2023 Outing Notes
Running down the hard but right path, staying focused with enduring passion.
道彤投资
@daltonventure
以生命科学为根，向硬科技生长
97 articles
Articles
Inside the Dalton Family | Mu Liyue of Lanji Medical: From Silicon Valley Back to Xi'an, I Want to Build a Laser Product That Truly Matters to Medicine
Changing the World Through "Medicine-Engineering Integration"
Inside Dalton Venture Family: BioCombo Therapeutics CEO on Pioneering EDP Platform to Produce High-Performance Chinese Membranes
World's First Electrochemical Deposition (EDP) Technology Platform
Inside Dalton Venture's Family of Companies | Boosting Long-Term Survival Rates with a Single Injection: How This Innovative Drug Developer Is Taking on Leukemia
CAR-T cell therapy is seen as a new hope in humanity's fight against cancer.
Into the Dalton Venture Family | Leveraging Two Technology Platforms — Low-Temperature Plasma and Radiofrequency Ablation — Favamed Charts a Platform Strategy
As of today, Fangrun Medical and its subsidiaries have secured 19 NMPA registrations. Its products are now used in over 1,200 hospitals across China, with successful exports to Europe and Southeast Asia, serving more than 100,000 patients annually.
Over 50,000 Cases in a Single Day! Inside the Speed of Landing AI's Cervical Cancer Screening | Dalton Venture Family
Landing Med aims to automate, digitize, and scale cytological pathology diagnosis through AI-powered, cloud-based diagnostic technology — enabling intelligent, networked, and standardized early detection of high-incidence tumors.
Into the Dalton Family | Melody Medical: Opening a New Chapter in RDN Therapy, Netrod® — China's Original Innovation — Takes the Global Stage
Hypertension is one of the most common diseases worldwide, severely impacting patients' health and quality of life. Nearly **1.28 billion adults** globally suffer from hypertension, yet awareness of the condition stands at just **54%**. Over 700 million hypertensive patients remain untreated, and only **21%** of adults with hypertension have their blood pressure under control. Prevention and treatment of hypertension carries profound significance for patients, families, and society at large.
Dalton Venture's Sun Qi: Prioritize Hard-Tech Sectors That Serve National Needs, Prioritize Solving Supply Chain Security Issues | Dalton Insights
At the "2023 China Investment Annual Conference" summit, Sun Qi shared his perspectives and experience with fellow guests on the topic of *How Much Longer Is the Window for Domestic Substitution in Medical Devices?*
A Visit to a Dalton Venture Family Company | Heyuan Bio's Lulu Lyu: China's Homegrown CAR-T Therapy Is About to Become Reality, Bringing New Hope for Relapsed or Refractory Acute Lymphoblastic Leukemia Patients
"After nearly five years, He Yuan Bio's first core product, inaticabtagene autoleucel injection, has treated more than 100 Chinese patients in clinical studies for acute lymphoblastic leukemia — representing the largest accumulated dataset to date on CD19 CAR-T clinical safety and efficacy in a Chinese patient population."
Dalton Venture's Lin Zhencheng: Technology Commercialization Gains Momentum, Capital Should Do More to Help Projects Cross the Commercialization Chasm | Dalton Insights
Dalton Venture's Lin Zhencheng was invited to participate in the Future Healthcare 100 · Trend Summit to discuss the next disruptive innovation track in life sciences.